GILEAD SCIENCES, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
GILEAD SCIENCES, INC. (GILD) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $8.31 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-24
- GILEAD SCIENCES, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $8.31B.
- GILEAD SCIENCES, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$876.00M, a 116.02% decline from fiscal 2023.
- GILEAD SCIENCES, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was $5.47B, a 23.16% increase from fiscal 2022.
- GILEAD SCIENCES, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was $4.44B, a 48.31% decline from fiscal 2021.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | $8.31B 10-K · filed 2026-02-24 |
| 2024-12-31 | -$876.00M 10-K · filed 2026-02-24 |
| 2023-12-31 | $5.47B 10-K · filed 2026-02-24 |
| 2022-12-31 | $4.44B 10-K · filed 2025-02-28 |
| 2021-12-31 | $8.59B 10-K · filed 2024-02-23 |
| 2020-12-31 | $2.50B 10-K · filed 2023-02-22 |
| 2019-12-31 | $4.11B 10-K · filed 2022-02-23 |
| 2018-12-31 | $7.07B 10-K · filed 2021-02-25 |
| 2017-12-31 | $8.10B 10-K · filed 2020-02-25 |
| 2016-12-31 | $7.65B 10-K · filed 2019-02-26 |
| 2015-12-31 | $7.95B 10-K · filed 2018-02-27 |
| 2014-12-31 | $6.68B 10-K · filed 2017-02-27 |
| 2013-12-31 | $3.47B 10-K · filed 2016-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |